Regeneus enters 2017 backed by transformational Japan deal

Regeneus (ASX:RGS) has a busy 2017 to come, spearheaded by its recent entry into the Japanese market for its Progenza product.

The company entered into a strategic collaboration and licensing agreement for the manufacture, clinical development and commercialisation of Progenza in Japan.

Read the full article by Proactive Investors here.